



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73
- (48) Corrigendum issued on:
02.08.2023 Bulletin 2023/31
- (45) Date of publication and mention of the grant of the patent:
05.07.2023 Bulletin 2023/27
- (21) Application number: **18729565.4**
- (22) Date of filing: **04.05.2018**
- (51) International Patent Classification (IPC):
A61K 38/08 ^(2019.01) **A61K 38/45** ^(2006.01)
A61K 39/00 ^(2006.01) **A61P 35/00** ^(2006.01)
C07K 7/06 ^(2006.01)
- (52) Cooperative Patent Classification (CPC):
(C-Sets available)
A61K 38/08; A61K 38/45; A61K 39/0011;
A61P 35/00; C07K 7/06; C12Y 207/07049 (Cont.)
- (86) International application number:
PCT/EP2018/061609
- (87) International publication number:
WO 2018/206462 (15.11.2018 Gazette 2018/46)

(54) **VACCINE TARGETING A CRYPTIC TERT EPITOPE, FOR TREATING LUNG CANCER IN A HLA-A*0201-POSITIVE NEVER-SMOKER OR LIGHT-FORMER SMOKER PATIENT**

IMPFSTOFF ZUR ABZIELUNG AUF EIN KRYPTISCHES TERT-EPITOP ZUR BEHANDLUNG VON LUNGENKREBS IN EINEM HLA-A*0201-POSITIVEN PATIENTEN, DER NIE ODER WENIGER GERAUCHT HAT

VACCIN CIBLANT UN ÉPITOPE TERT CRYPTIQUE, POUR LE TRAITEMENT DU CANCER DU POUMON CHEZ UN NON FUMEUR POSITIF AU HLA-A*0201 OU CHEZ UN PATIENT ANCIEN FUMEUR LÉGER

- | | |
|---|---|
| <p>(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR</p> <p>(30) Priority: 09.05.2017 EP 17305527</p> <p>(43) Date of publication of application:
15.04.2020 Bulletin 2020/16</p> <p>(73) Proprietor: Kriptic Pharmaceuticals Limited
Dublin 1 (IE)</p> <p>(72) Inventors:
• KOSMATOPOULOS, Kostantinos (Kostas)
75005 Paris (FR)
• MENEZ-JAMET, Jeanne
92120 Montrouge (FR)</p> | <p>(74) Representative: Santarelli
Tour Trinity
1 bis Esplanade de la Défense
92035 Paris La Défense Cedex (FR)</p> <p>(56) References cited:
WO-A2-2006/120038</p> <p>• ELENI-KYRIAKIVETSIKA ET AL: "Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 2, 20 August 2011 (2011-08-20), pages 157-168, XP035005847, ISSN: 1432-0851, DOI: 10.1007/S00262-011-1093-4</p> |
|---|---|

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- LAN QING ET AL: "Longer Telomere Length in Peripheral White Blood Cells Is Associated with Risk of Lung Cancer and the rs2736100 (CLPTM1L-TERT) Polymorphism in a Prospective Cohort Study among Women in China", PLOS ONE, vol. 8, no. 3, March 2013 (2013-03), XP055415765, ISSN: 1932-6203
 - N. A. RIZVI ET AL: "Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", SCIENCE, vol. 348, no. 6230, 3 April 2015 (2015-04-03), pages 124-128, XP055322846, ISSN: 0036-8075, DOI: 10.1126/science.aaa1348
 - ZHANG TENGFEI ET AL: "The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis", ONCOTARGET, vol. 7, no. 45, 8 November 2016 (2016-11-08), pages 73068-73079, XP055415778,
 - DOGAN SNJEZANA ET AL: "Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers", CLINICAL CANCER RESEARCH, vol. 18, no. 22, November 2012 (2012-11), pages 6169-6177, XP055415781,
 - BUCCHERI G ET AL: "Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 32, no. 7, 1 June 1996 (1996-06-01), pages 1135-1141, XP027246652, ISSN: 0959-8049 [retrieved on 1996-06-01]
 - TOMOHIRO TAMURA ET AL: "Specific organ metastases and survival in metastatic non-small-cell lung cancer", MOLECULAR AND CLINICAL ONCOLOGY, vol. 3, no. 1, 4 September 2014 (2014-09-04), pages 217-221, XP055497469, GR ISSN: 2049-9450, DOI: 10.3892/mco.2014.410
- (52) Cooperative Patent Classification (CPC): (Cont.)
- C-Sets
A61K 38/08, A61K 2300/00;
A61K 39/0011, A61K 2300/00